Market Mover | Eli Lilly Shares Rise 4% as its Weight Loss Drug Reduces Heart Failure Risk in Trial
Market Mover | Eli Lilly Shares Rise 4% as its Weight Loss Drug Reduces Heart Failure Risk in Trial
August 1, 2024 - $Eli Lilly and Co (LLY.US)$shares increased 4.11% to $837.36 in trading on Thursday.
2024年8月1日 - $禮來 (LLY.US)$週四交易中股價上漲4.11％，至837.36美元。
Eli Lilly announced today its weight-loss drug tirzepatide could significantly improve heart failure symptoms and physical limitations, reducing the risk of heart failure outcomes by 38% compared to placebo in phase 3 clinical trial. The company will submit results to the FDA and other regulatory agencies starting later this year.
艾力禮今日宣佈，其減重藥物tirzepatide在3期臨床試驗中可以顯著改善心衰症狀和身體功能，相比安慰劑降低心衰終局風險38%。公司將於今年晚些時候向FDA和其他監管機構提交結果。
Tirzepatide is marketed as Mounjaro for diabetes treatment and Zepbound for weight loss and is administered by injection.
Tirzepatide作爲治療糖尿病的Mounjaro和用於減肥的Zepbound的市場，需通過注射給藥。
In addition, Morgan Stanley Wealth Management increases internally held portfolio weights in Eli Lilly.
此外，摩根士丹利财富管理部門增加了對伊萊利利公司內部持有投資組合的權重。